Oventus names new CEO, reports results
By HME News Staff
Updated 9:36 AM CST, Mon January 31, 2022
BRISBANE, Australia – Oventus Medical has announced that John Cox will replace Dr. Chris Hart as CEO on Feb. 1. Hart will remain executive director and will also take on the new role of chairman of the Scientific Advisory Board to lead scientific and clinical research projects designed to position the company’s O2Vent Opima technology as the first choice for patients and clinicians for the treatment of OSA. “On behalf of the board, I want to thank Chris for his leadership and the many significant contributions he’s made to Oventus since the company’s inception,” said Sue MacLeman, chairperson. “He invented the technology, founded the company, and has led Oventus through its early stages with conviction and passion. Now, Chris would like to return over time to his clinical practice and devote more time to the advancement of the O2Vent technology. “We are grateful to be able to retain Chris’ substantial clinical skillset and corporate knowledge as John makes his planned transition into the role of CEO.” Cox has a strong track record in successfully commercializing medtech therapeutics, including those for obstructive sleep apnea, Oventus says. The company also announced financial results for the quarter ended December, including total revenue increased 51% to $334,000 and revenue for O2Vent, specifically, increased 39%. Other highlights: Direct-to-consumer marketing drove an 88% increase in active leads compared to the prior quarter and completed telehealth consults nearly doubled to 1,318.
Comments